{"analyses":[{"ciPctValue":"95","groupDescription":"Any Improvement","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","statisticalMethod":"Fisher Exact"},{"ciPctValue":"95","groupDescription":"Erythroid Response - Major","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","statisticalMethod":"Fisher Exact"},{"ciPctValue":"95","groupDescription":"Erythroid Response - Minor","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.6203","statisticalMethod":"Fisher Exact"},{"ciPctValue":"95","groupDescription":"Platelet Response - Major","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0003","statisticalMethod":"Fisher Exact"},{"ciPctValue":"95","groupDescription":"Platelet Response - Minor","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.7514","statisticalMethod":"Fisher Exact"},{"ciPctValue":"95","groupDescription":"Neutrophil Response - Major","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.8695","statisticalMethod":"Fisher Exact"},{"ciPctValue":"95","groupDescription":"Neutrophil Response - Minor","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.1760","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"51"}]}],"title":"Any Improvement n=177, 178"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"17"}]}],"title":"Erythroid Response - Major n=157, 160"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Erythroid Response - Minor n=157, 160"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"18"}]}],"title":"Platelet Response - Major n=141, 129"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}]}],"title":"Platelet Response - Minor n=138, 127"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"20"}]}],"title":"Neutrophil Response - Major n=131, 111"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"}]}],"title":"Neutrophil Response - Minor n=131, 111"}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"IWG 2000 Criteria: Pretreatment=hemoglobin \\<100g/L or RBC transfusion-dependent, platelet count \\<100x10\\^9/L or platelet transfusion dependent, absolute neutrophil count \\<1.5x10\\^9/L.\n\nErythroid response: Major-\\>20g/L increase or transfusion independent. Minor- 10-20g/L increase or \\>=50% decrease in transfusion requirements.\n\nPlatelet response: Major-absolute increase of \\>=30x10\\^9/L or platelet transfusion independence. Minor-\\>=50% increase.\n\nNeutrophil response: Major-\\>=100% increase or an absolute increase of \\>0.5x10\\^9/L. Minor-\\>=100% increase and absolute increase of \\<0.5x10\\^9/L.","groups":[{"description":"Azacitidine, 75 mg/m\\^2/day given by subcutaneous injection for 7 days of every 28 day cycle, plus best supportive care.","id":"OG000","title":"Azacitidine"},{"description":"Physician choice of low dose cytarabine, standard chemotherapy, or best supportive care (consisting of blood products, growth factors, antibiotics)","id":"OG001","title":"Conventional Care"}],"paramType":"NUMBER","populationDescription":"Intent to treat population.","reportingStatus":"POSTED","timeFrame":"Day 1 to 42 months","title":"Number of Participants Showing Hematologic Improvement Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS) Assessed by Independent Review Committee","type":"SECONDARY","unitOfMeasure":"participants"}